Opendata, web and dolomites

IMMUNOTRAP SIGNED

Diagnosis test for immuno-oncology therapies.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNOTRAP project word cloud

Explore the words cloud of the IMMUNOTRAP project. It provides you a very rough idea of what is the project "IMMUNOTRAP" about.

impetux    flow    surface    create    immunotherapies    cells    interact    physics    measured    awarded    tumors    assessing    resonance    efforts    innovation    opportunity    diagnosis    recognition    unmet    marketing    heterogeneity    performance    receptors    act    optical    prize    homogeneous    fundamental    generally    ground    industry    genetic    contact    platform    ago    few    solution    market    cell    breaking    samples    adoptive    thanks    efficient    affinity    personalised    differently    confirm    cancers    immunoassays    immunotrap    1980s    invention    selecting    drugs    company    commercial    until    forces    clinical    laser    screening    endpoint    light    mechanically    nobel    pharmaceutical    start    force    binding    intellectual    transferring    entry    cytometry    drifting    transfer    boost    offers    physical    uses    oncology    plasmon    exhibit    techniques    patient    disrupting    suitable    interaction    precisely    inmuno    workhorse    tweezers    immune    father    therapies    back    routes    technique    mutations    characterization    successful    2018    cancer    treatments   

Project "IMMUNOTRAP" data sheet

The following table provides information about the project.

Coordinator
IMPETUX OPTICS SL 

Organization address
address: CALLE TRIAS I GIRO 15
city: BARCELONA
postcode: 8034
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPETUX OPTICS SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cancers exhibit a large heterogeneity in terms of genetic mutations, so they respond differently to the same drugs. This is why oncology is rapidly drifting towards treatments with new disrupting personalised inmuno-oncology therapies based on adoptive T-cell transfer (ACT). These therapies aim at selecting the most efficient T cells against tumors and transferring them back to the patient. This kind of Immunoassays are generally carried out with endpoint measurements like Surface Plasmon Resonance or Flow Cytometry. However, these techniques do not allow assessing the binding process between the immune and the target cell, which represents a fundamental step of the recognition phase where large efforts against cancer focus. IMPETUX has developed a solution to address this unmet need. The characterization of this affinity will be achieved through the measurement of the interaction force between them with IMMUNOTRAP: a platform for cell screening based on IMPETUX‘s optical tweezers. This technology uses a highly-focused laser light to mechanically interact with the sample without physical contact. The recent 2018 Nobel Prize in Physics was awarded to the intellectual father of this technique for his ground-breaking invention in the 1980s. However, it was not until few years ago that forces could start being measured on non-homogeneous samples, such as cells, thanks to the technology developed by IMPETUX. The IMMUNOTRAP has the potential to become the workhorse in the screening of the best performance receptors for their use in immunotherapies and offers IMPETUX the opportunity to address a high-growth potential market: the pharmaceutical industry and clinical diagnosis. It represents, therefore, a key opportunity to boost the company’s growth. Thus, the objectives of the present innovation project is precisely to confirm the potential of the proposal to create value and to identify the most suitable marketing and commercial routes for a successful market entry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOTRAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOTRAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More